T he innate immune system, also known as the non-specific immune system, is the first line of defense utilized by the host to provide protection against infection by organisms. In order to combat infection by bacteria, viruses or fungi, host cells have evolved a repertoire of sophisticated systems to sense infection and trigger innate immune responses, through the engagement of Toll-like receptors (TLRs) or other pattern-recognition receptors on the cell surface. 1 Upon the activation of pattern-recognition receptor, various immune responses are initiated, leading to the production of a variety of cytokines and pro-inflammatory factors such as type I interferons (IFN-a and IFN-b) by dendritic cells (DCs). 2 However, these normally beneficial responses may lead to pathological consequences if they are not tightly controlled. For example, systemic autoimmune diseases, such as systemic lupus erythematosus (SLE), systemic sclerosis and Sjogren's syndrome, develop in response to continuous inflammatory signals, which create a feedback amplification loop for autoimmune responses. 3 One easy and efficient strategy for blocking extensive immune responses to infection is to inhibit the activity and/or level of key signaling molecules that mediate these responses. E3 ubiquitin ligases play an important role in the regulation of immune receptor signaling and the maintenance of immune homeostasis. 4 The tripartite motif-containing (TRIM) proteins belong to a superfamily that is conserved throughout the metazoan kingdom. Until now, more than 60 TRIM proteins have been identified in humans and mice, and most of them contain a RING domain in their N-terminal region. The RING domains of many TRIM family members have been shown to confer E3 ubiquitin ligase activity. This activity allows these proteins to mediate ubiquitination events, which are crucial in the negative regulation of innate immunity. 5 For example, an early study has shown that TRIM30a promotes the ubiquitination and degradation of TAB2 and TAB3, resulting in the inhibition of TNFRassociated factor 6 ubiquitination and the inhibitionofNF-kBactivity.Consequently, the induction of pro-inflammatory cytokines by TLR-mediated NF-kB activation is inhibited. 6 Recently, TRIM38 was shown to negatively regulate TLR signaling and thus prevent excessive TLR-induced inflammatory responses, through promoting Lys48 (K48)-linked ubiquitination and degradation of TNFRassociated factor 6.
7 Furthermore, TRIM38 interacted with NF-kB-activating kinaseassociated protein 1, which is essential for TLR-induced IFN regulatory factor 3 activation and IFN-b production. As an E3 ligase, TRIM38 promoted K48-linked ubiquitination and degradation of NF-kB-activating kinase-associated protein 1, thus negatively regulating TLR and RIG-I-mediated IFN-b production. 8 In addition, a very recent study identified TIR domain-containing adaptor inducing IFN-b as a new E3 target of TRIM38 and suggested that TRIM38 may act as a novel negative regulator for TLR3-mediated type I IFN signaling by targeting TIR domain-containing adaptor inducing IFN-b for degradation. 9 Strikingly, most TRIM genes are upregulated following virus infection or following the activation of TLR signaling in a type-I IFN dependent manner, and most contain an IFN-stimulated response element in their promoter. Taken together, these data suggest that TRIM proteins constitute an important negative feedback loop for restricting the immune response to a proper level. Now, in a study recently published in Nature Immunology, Zhang et al. provide further testimony to the sophisticated negative feedback machineries used by host cells to keep the immune response under control. Zhang et al. 10 demonstrate that TRIM21 is an IFN-inducible E3 ligase that induces K48-linked ubiquitination and degradation of DDX41 and negatively regulates the innate immune response to intracellular double stranded DNA (dsDNA). Host cells are known to be constantly exposed to dsDNA that is released from damaged host cells or introduced by DNA viruses and intracellular bacteria during infection. Zhang et al. 11 have previously reported that DDX41, a member of the DEXDc family of helicases, is an intracellular DNA sensor in myeloid dendritic cells (mDCs) and that sensing of DNA by this molecule results in type I IFN and cytokine responses to DNA and DNA viruses. 11 To further understand the regulation of DDX41 function in dsDNA induced innate immune responses, in the current study, the authors performed mass spectrometry-based proteomic analysis to screen DDX41 interacting proteins, and they identified the E3 ubiquitin ligase TRIM21 as an important partner of DDX41.
Next, the authors characterized the functional interaction between DDX41 and TRIM21 in mDCs. By establishing stable mDC cell lines in which DDX41 and TRIM21 are knocked down, as well as using DCs derived from TRIM21-deficient mice, the authors found that TRIM21 negatively regulated the DDX41 expression level and the production of IFN-b in DCs exposed to intracellular DNA and DNA viruses. Furthermore, the authors examined the effects of TRIM21 on the downstream signaling by DDX41 in the sensing of intracellular DNA in mDCs. The results showed that TRIM21 inhibited the signaling cascade downstream of DDX41, leading to the inhibition of type-I IFN responses upon dsDNA stimulation. Importantly, the authors showed that the expression of TRIM21 was upregulated in mDCs stimulated by poly(dA:dT) or poly(I:C), confirming the previous results that TRIM21 is inducible by type I IFN and supporting the view that TRIM genes are upregulated following the activation of TLR signaling in a type-I IFN dependent manner. 12 The authors went on to characterize the physical interaction between DDX41 and TRIM21. Serial truncations of DDX41 and TRIM21 showed that the DEADc domain of DDX41 and the SPRY-PRY domain of TRIM21 mediated the interaction between DDX41 and TRIM21. Immunofluorescence staining further showed that TRIM21 and DDX41 were co-localized in the cytosol under resting conditions and that TRIM21 was dissociated from DDX41 after dsDNA stimulation. Biochemical analysis showed that TRIM21 induced the K48-linked ubiquitination and degradation of DDX41, but had no effects on the ubiquitination and degradation of other sensors of viral DNA such as LRRFIP1, p204 and DAI, suggesting the substrate specificity of DDX41 for TRIM21. Lastly, the authors identified Lys9 and Lys115 of DDX41 as the ubiquitination sites for TRIM21 and demonstrated that these two residues are crucial for the downstream effects of TRIM21.
As often happen with scientific endeavor, more questions have been raised than answered. In this study, the authors reported that in THP-1 human monocyte cells, the knockdown of TRIM21 enhanced the production of IFN-b in response to intracellular DNA or HSV-1. However, further knockdown of TRIM21 in THP-1 cells in which DDX41 had been knocked down had no effect on the production of IFN-b. These results suggest that the function of TRIM21 in regulating IFN-b production is completely dependent on DDX41. Nevertheless, an early study has shown that TRIM21 could negatively regulate IFN-b production post-pathogen recognition by acting as an E3 ubiquitin ligase to promote the degradation of IFN regulatory factor IRF3. 13 Further investigations are needed to address such inconsistencies, which may be caused by differences in the cells and the stimuli used.
In summary, the striking findings presented in this study provide new insight into the regulatory mechanisms by which host cells sense dsDNA and subsequently initiate type I IFN responses (to initiate innate immune responses) and induce E3 ubiquitin ligases, resulting in the degradation of the dsDNA sensor in a timely manner to terminate the innate immune response (Figure 1) . In addition, the dsDNA-DDX41-type I IFN-TRIM21 axis that the authors identified in this study may have important clinical significance. Disruption of this axis may lead to either an insufficient immune response, and thus the failure of host defense, or an overactive immune response as in the cases of autoimmune disease, including SLE, systemic sclerosis and Sjogren's syndrome. Indeed, TRIM21 has been reported to be an autoantigen (RO52 or SS-A) for patients with SLE and Sjögren's syndrome, and Ro52 polymorphisms have been described to be associated with SLE and Sjogren's syndrome. 14, 15 Given that TRIM21 acts as a negative regulator of sensors of dsDNA, increasing the activity and/or level of TRIM21 could be beneficial for controlling autoimmune diseases such as SLE. Therefore, TRIM21-targeted therapy may present a novel strategy for treating autoimmune diseases. Figure 1 Proposed model for the dsDNA-DDX41-type I IFN-TRIM21 axis to regulate innate immune responses. Upon virus infection and the release of dsDNA into the cytoplasm, DDX41 senses dsDNA and activates the transcription of type I IFN, leading to an innate immune response. At the same time, type I IFN induces the transcription of TRIM21, which acts as an E3 ubiquitin ligase, promoting K48-linked polyubiquitination of DDX41. The ubiquitinated DDX41 undergoes proteasome-mediated degradation and therefore cannot sense dsDNA. Consequently, the innate immune response is terminated. dsDNA, double stranded DNA; IFN, interferon; TRIM, tripartite motif.
